Needham Maintains Buy on Harmony Biosciences Hldgs, Lowers Price Target to $44
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Needham analyst Ami Fadia maintains Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Buy and lowers the price target from $46 to $44.
Needham analyst Ami Fadia maintains Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Buy and lowers the price target from $46 to $44.